University of Groningen

Metabolic-associated fatty liver disease

Prins, Grietje Harmanna

DOI:
[10.33612/diss.204505585](https://doi.org/10.33612/diss.204505585)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Prins, G. H. (2022). *Metabolic-associated fatty liver disease: a major problem miniaturised*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.204505585>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Metabolic- Associated Fatty Liver Disease

*A major problem
miniaturized*

A circular watercolor splash with a gradient from yellow to green to blue, positioned behind the subtitle text.

Grietje H. Prins

2022

This PhD project was financially supported by by Prof. Dr. H.W. Frijlink (Groningen Research Institute of Pharmacy).

The research described in this thesis was carried out at the department of Pharmaceutical Technology and Biopharmacy (University of Groningen), in collaboration with the departments of Hepato- Pancreato- Biliary Surgery and Liver Transplantation (University Medical Center Groningen; UMCG) Pathology and Medical Biology (UMCG), Systems Biology (UMCG), and Boehringer Ingelheim Pharma GmbH & Co. KG.

Paranymphs

Manita H.G. Prins

Renée S. van der Kooij

Metabolic-associated fatty liver disease

A major problem miniaturized

Layout design: Gerian Prins & Emilia Bigaeva

Cover design: Gerian Prins & Emilia Bigaeva

Printing: Ipskamp Printing, Enschede

ISBN (printed): 978-94-6421-664-6

© Copyright 2022, G.H. Prins

All rights are reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or mechanical, without permission of the author.

/ university of
groningen

Metabolic-associated fatty liver disease

A major problem miniaturized

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

dinsdag 15 maart 2022 om 14.30 uur

door

Grietje Harmanna Prins

geboren op 21 april 1992
te Emmen

Promotores

Prof. dr. P. Olinga

Prof. dr. F.J. Dekker

Beoordelingscommissie

Prof. dr. K.N. Faber

Prof. dr. J.W. Jonker

Prof. dr. J. Lykkesfeldt

Table of CONTENTS

1	General introduction	8
---	----------------------	---

Part I – *Induction*

2	A pathophysiological model of metabolic-associated fatty liver disease using rodent precision-cut liver slices	32
---	--	----

3	Pathophysiological induction of early-stage metabolic-associated fatty liver disease in human liver tissue	56
---	--	----

Part II – *Intervention*

4	The effects of α -linolenic acid, γ -linolenic acid and lipoxygenase activity on metabolic-associated fatty liver disease ex vivo	98
---	---	----

5	The effects of butyrate on induced metabolic-associated fatty liver disease in precision-cut liver slices	126
---	---	-----

6	Transcription factor ligands reduce steatosis in a human model for metabolic-associated fatty liver disease	154
---	---	-----

7	General discussion	182
---	--------------------	-----

Appendices

COVID-19 & this thesis	216
Samenvatting & summary	224
Abbreviations	232
Author affiliations	236
About the author	234
Acknowledgements	238